GLOBAL INHALATION DRUG DELIVERY DEVICES MARKET

EXECUTIVE SUMMARY

i. Respiratory disease prevalence 
ii. Inhalation drug delivery devices market 
	a. Selected market drivers and limiters 
	b. Asthma-related devices segment 
	c. COPD-related devices segment
	d. Market leaders
	e. Emerging competition
iii. Methodology

Exhibit ES-1: Inhalation drug delivery devices market forecast, by segment, 2016-21
Exhibit ES-2: Inhalation drug delivery devices market forecast, by region, 2016-21

1. INHALATION DRUG DELIVERY TECHNOLOGY
 
1.1 Technology
	1.1.1 Metered dose inhalers
		1.1.1.1 Breath-actuated MDIs 
		1.2.1.2 Spacers for use with MDIs 
	1.2.2 Dry powder inhalers 
	1.1.3 Nebulizers 

2. INHALATION DEVICES FOR ASTHMA

2.1 Epidemiology
2.2 Products 
	2.2.1 Regulatory guidelines
	2.2.2 AstraZeneca
	2.2.3 Boehringer Ingelheim 
	2.2.4 GlaxoSmithKline
	2.2.5 Merck & Co
	2.2.6 SkyePharma/Vectura 
	2.2.7 Emerging products 
2.3 Market analysis 
	2.3.1 Advair and Breo
	2.3.2 Dulera
	2.3.3 Flutiform 
	2.3.4 Spiriva 
	2.3.5 Symbicort 
	2.3.6 Combined market forecast 
	2.3.7 US market forecast
	2.3.8 5EU market forecast
	2.3.9 Japan market forecast
2.4 Bibliography

Exhibit 2-1: Asthma, epidemiology, 2015-34 
Exhibit 2-2: Selected inhaled asthma treatment products, 2017 
Exhibit 2-3: Asthma market, forecasting methodology 
Exhibit 2-4: Inhaled asthma treatment products, combined market forecast, 2016-21 
Exhibit 2-5: Inhaled asthma treatment products, US market forecast, 2016-21 
Exhibit 2-6: Inhaled asthma treatment products, 5EU market forecast, 2016-21 
Exhibit 2-7: Inhaled asthma treatment products, Japan market forecast, 2016-21 

3. INHALATION DEVICES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
 
3.1 Epidemiology
3.2 Products 
	3.2.1 AstraZeneca
	3.2.2 Boehringer Ingelheim 
	3.2.3 GlaxoSmithKline
	3.2.4 Merck & Co
	3.2.5 Novartis 
	3.2.6 Sunovion Pharmaceuticals 
	3.2.7 Teva 
	3.2.8 Emerging products 
3.3 Market analysis 
	3.3.1 Duaklir, PT010, Symbicort, and Tudorza
	3.3.2 Spiriva, Stiolto, and Striverdi 
	3.3.3 CHF 5993
	3.3.4 Advair, Breo, Anoro, FF/UMEC/VI, and Incruse 
	3.3.5 Dulera
	3.3.6 Arcapta, Seebri, Utibron 
	3.3.7 Combined market forecast 
	3.3.8 US market forecast
	3.3.9 5EU market forecast
	3.3.10 Japan market forecast
3.4 Bibliography

Exhibit 3-1: Chronic obstructive pulmonary disease, epidemiology, 2016-36
Exhibit 3-2: Selected inhaled COPD treatment products, 2017
Exhibit 3-3: COPD market, forecasting methodology 
Exhibit 3-4: Inhaled COPD treatment products, combined market forecast, 2016-21 
Exhibit 3-5: Inhaled COPD treatment products, US market forecast, 2016-21 
Exhibit 3-6: Inhaled COPD treatment products, 5EU market forecast, 2016-21 
Exhibit 3-7: Inhaled COPD treatment products, Japan market forecast, 2016-21 

APPENDIX: COMPANY LISTING

1. AstraZeneca PLC
2. Boehringer Ingelheim GmbH
3. Chiesi Farmaceutici SpA
4. GlaxoSmithKline PLC
5. Merck & Co, Inc.
6. Novartis AG
7. Pfizer, Inc.
8. Roche Pharmaceuticals/F. Hoffman-La Roche LTD
9. SkyePharma PLC/Vectura Group PLC
10. Sunovion Pharmaceuticals, Inc.
11. Teva Pharmaceutical Industries LTD